Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 43 peer-reviewed journal articles Updated
Dermatology

Your Skin and Primary Cutaneous Amyloidosis

At a Glance

Primary Cutaneous Amyloidosis (PCA) is a localized, non-life-threatening skin condition caused by abnormal protein buildup from scratching, friction, or genetics. Unlike systemic amyloidosis, PCA does not affect internal organs. Management focuses on relieving itch and improving skin appearance.

Receiving a diagnosis of amyloidosis can be frightening because the term is often associated with serious, organ-threatening diseases. However, Primary Cutaneous Amyloidosis (PCA) is a distinct, localized condition where the issue is confined strictly to the skin [1][2]. Understanding that this is a dermatological (skin-focused) concern rather than a systemic (whole-body) illness is the first and most important step in managing your diagnosis [1].

At its core, PCA involves the buildup of amyloid, which are abnormal clusters of proteins that have folded into a shape the body cannot easily break down [3][4]. In PCA, these proteins are usually derived from your own skin cells (keratinocytes) [3][5]. Unlike systemic forms of amyloidosis, these deposits do not travel through the bloodstream to reach your heart, kidneys, or liver [2][6].

There are three main types of PCA (along with a common mixed type called Biphasic Amyloidosis):

  • Lichen Amyloidosis: The most common form, appearing as small, itchy, thickened bumps.
  • Macular Amyloidosis: Characterized by flat, darkened, or dusky patches of skin.
  • Nodular Amyloidosis: A rare form involving firmer, larger lumps.

For more detailed information, explore the following pages in this guide:

01

The Subtypes: Macular, Lichen, Nodular, and Biphasic

Learn the 4 subtypes of primary cutaneous amyloidosis: macular, lichen, biphasic, and nodular. Understand your symptoms, skin changes, and what causes them.

02

Biopsies and Pathology Reports

Learn how to read your primary cutaneous amyloidosis (PCA) pathology report. Understand your skin biopsy results, Congo Red staining, and CK5/6 testing.

03

Treatment Strategies and Daily Management

Explore treatments for primary cutaneous amyloidosis (PCA). Learn how to manage intense itching, use topical therapies, and build a daily skin care routine.

04

Systemic Risk and Rare Associations

Learn about the rare systemic risks associated with Primary Cutaneous Amyloidosis (PCA). Understand links to MEN2A, systemic AL amyloidosis, and Sjögren's.

Scientists have identified two primary factors that contribute to the development of PCA: friction and genetics. For many years, the leading theory has been the friction hypothesis. This suggests that chronic scratching, rubbing, or the use of coarse tools like nylon towels causes damage to skin cells [7][8]. When these cells (keratinocytes) are damaged repeatedly, they release proteins that eventually transform into amyloid deposits [3][9]. In some cases, PCA runs in families, particularly in Southern Chinese populations, due to mutations in specific genes [10][11].

The general prognosis for PCA is excellent regarding your overall health. Because it does not involve internal organs, it is not life-threatening [1][2]. However, PCA is considered a chronic (long-term) condition. Your care team will focus on keeping your skin comfortable and managing any cosmetic concerns you may have.

Common questions in this guide

Is primary cutaneous amyloidosis life-threatening?
No, primary cutaneous amyloidosis is strictly a localized skin condition. Unlike systemic amyloidosis, it does not involve internal organs like the heart or kidneys, making it completely non-life-threatening.
What causes primary cutaneous amyloidosis?
The condition is primarily caused by chronic friction or scratching, which damages skin cells and causes them to release proteins that form amyloid deposits. Genetics and family history can also play a significant role in its development.
What are the different types of skin amyloidosis?
The three main types are lichen amyloidosis, which appears as itchy, thickened bumps, and macular amyloidosis, which causes flat, darkened skin patches. A rarer form, nodular amyloidosis, involves firmer, larger lumps on the skin.
Do I need blood tests or imaging to confirm this is localized?
Since primary cutaneous amyloidosis is confined to the skin, extensive blood tests or imaging are generally not required to check your organs. Your doctor may only suggest them if they suspect the rare nodular subtype or need to rule out a systemic connection.
Will my skin lesions spread or change over time?
While the condition is chronic and the lesions may persist, it generally remains strictly localized to your skin. Your dermatologist can help monitor your skin over time and provide therapies to manage the itching and appearance of the spots.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I need any blood tests or imaging to confirm this is localized only to my skin?
  2. 2.Since my condition is limited to the skin, what are my options for managing the itch and the appearance of the lesions?
  3. 3.What is the likelihood that my skin lesions will spread or change over time?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Clinical resolution of generalized lichen amyloidosis with dupilumab: a new alternative therapy.

    Humeda Y, Beasley J, Calder K

    Dermatology online journal 2020; (26(12)).

    PMID: 33423428
  2. 2

    Tofacitinib for the treatment of primary cutaneous amyloidosis: A case report.

    Chen J, Yang B

    Dermatologic therapy 2022; (35(4)):e15312 doi:10.1111/dth.15312.

    PMID: 35001465
  3. 3

    34βE12 is the Most Reliable Marker for Keratin-Derived Cutaneous Amyloid: A Comparative Study.

    Daruish M, Al-Sharbatee G, D'Arrigo C, Taibjee S

    The American Journal of dermatopathology 2025; (47(6)):439-441 doi:10.1097/DAD.0000000000002942.

    PMID: 39983073
  4. 4

    Nodular Cutaneous Amyloidosis on the Nose Confirmed Using Electron Microscopy: A Case Report.

    Choi GW, Kim DH

    Annals of dermatology 2023; (35(Suppl 2)):S376-S377 doi:10.5021/ad.22.075.

    PMID: 38061751
  5. 5

    Primary cutaneous amyloidosis: A clinicopathological, histochemical, and immunohistochemical study.

    Sinha A, Manjunath GV, Basavaraj V

    Indian journal of pathology & microbiology 2021; (64(2)):323-328 doi:10.4103/IJPM.IJPM_32_20.

    PMID: 33851627
  6. 6

    Primary cutaneous nodular amyloidosis associated with the injection of autologous fat.

    Mena L, Carrasco C, Folch H, et al.

    Clinical and experimental dermatology 2021; (46(3)):552-554 doi:10.1111/ced.14429.

    PMID: 32844397
  7. 7

    A Case Report of Generalized Non-pruritic Lichen Amyloidosis.

    Rousseau MA, Valek SA, Rashid RM

    Cureus 2023; (15(6)):e39817 doi:10.7759/cureus.39817.

    PMID: 37397685
  8. 8

    Secondary Localized Cutaneous Amyloidosis is not Rare in Bowen's Disease and Bowenoid Papulosis.

    Baykal C, Hurdogan O, Kobaner GB, et al.

    Turk patoloji dergisi 2022; (38(1)):54-59 doi:10.5146/tjpath.2021.01530.

    PMID: 34514563
  9. 9

    The therapeutic effects of 1540-nm nonablative fractional erbium laser on macular amyloidosis: a randomized clinical trial.

    Nahidi Y, Delghandi SR, Kiafar B, Saki A

    The Journal of dermatological treatment 2021; (32(3)):340-344 doi:10.1080/09546634.2019.1655136.

    PMID: 31411528
  10. 10

    [Identification of pathogenic mutations in two Chinese families affected with primary localized cutaneous amyloidosis].

    Mao B, Yao X, Wang Z, Zhao X

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2018; (35(1)):9-13 doi:10.3760/cma.j.issn.1003-9406.2018.01.002.

    PMID: 29419851
  11. 11

    Clinical and genetic features of Chinese patients with lichen and macular primary localized cutaneous amyloidosis.

    Lu P, Wu FF, Rong ZL, et al.

    Clinical and experimental dermatology 2019; (44(4)):e110-e117 doi:10.1111/ced.13925.

    PMID: 30734345

This page provides an educational overview of Primary Cutaneous Amyloidosis. It is not a substitute for professional medical advice, diagnosis, or treatment from a board-certified dermatologist.

Get notified when new evidence is published on Primary cutaneous amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.